CBAY - CymaBay Therapeutics, Inc.
After hours:
Chart Events
Momentum
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 9.41 |
| Open | 9.38 |
| Bid | 9.56 x 800 |
| Ask | 9.57 x 2200 |
| Day's Range | 9.33 - 9.61 |
| 52 Week Range | 1.81 - 11.22 |
| Volume | |
| Avg. Volume | 1,579,990 |
| Market Cap | 936.127M |
| Beta (5Y Monthly) | 0.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.26 |
| Earnings Date | Aug 09, 2023 - Aug 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.20 |
Fair Value
Related Research
Motley FoolWhy CymaBay Therapeutics Stock Nose-Dived This Week
A significant miss on quarterly earnings combined with a big change in its C-suite put a damper on CymaBay Therapeutics (NASDAQ: CBAY) stock this week. According to data compiled by S&P Global Market Intelligence, the biotech's stock suffered an 11% decline over that stretch of time as a result. The biotech's earnings release also served as a business update for its shareholders and other interested parties.
- Thomson Reuters StreetEvents
Q1 2023 CymaBay Therapeutics Inc Earnings Call
Q1 2023 CymaBay Therapeutics Inc Earnings Call
ZacksCymaBay Therapeutics Inc. (CBAY) Is a Great Choice for 'Trend' Investors, Here's Why
CymaBay Therapeutics Inc. (CBAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
GlobeNewswireCymaBay Reports First Quarter 2023 Financial Results and Provides Corporate Update
Harish Shantharam, proven leader in building financial organizations to prepare for successful commercialization, appointed as Chief Financial Officer Results from ENHANCE phase 3 global study of seladelpar in patients with PBC published in Hepatology Completed a public equity offering totaling net proceeds of $92.4 million Entered into a collaboration and license agreement with Kaken Pharmaceutical Co., Ltd. Conference call and webcast today at 4:30 p.m. ET NEWARK, Calif., May 15, 2023 (GLOBE N
- GlobeNewswire
CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023
NEWARK, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Monday, May 15, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2023 and to provide a business update. Conference Call DetailsTo access the live c
- GlobeNewswire
CymaBay Names Harish Shantharam Chief Financial Officer
Proven Leader in Building Financial Organizations to Prepare Company for Successful Commercialization Planning for Seladelpar Launch as it Completes Development and Regulatory Submissions NEWARK, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that seasoned biopharma executive Harish Shantharam, CFA has joined th
Simply Wall St.Institutional investors own a significant stake of 45% in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)
Key Insights Significantly high institutional ownership implies CymaBay Therapeutics' stock price is sensitive to their...
TipRanksBillionaire Joseph Edelman Snaps Up These 2 Biotech Stocks — Here’s Why You Should Follow
American ingenuity has long been the driving force behind the US economy, and few sectors embody this better than biotech. With over 500 biotech firms operating in the US, developing new medical technologies, drug therapies, surgical instruments, and techniques – the list is only limited by imagination. These brilliant vistas come with risks, though, including biotech’s famously high overhead costs, its long lead times to new product introduction, and the burden of regulatory requirements and ap
- GlobeNewswire
CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)
NEWARK, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results from the ENHANCE phase 3 global study evaluating seladelpar for primary biliary cholangitis (PBC) have been published in Hepatology: Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE,
- GlobeNewswire
CymaBay Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
NEWARK, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ. H.C. Wainwright BioConnect Investor Conference at NASDAQDate: Tuesday, May 2Time: 9:00 am Eastern TimeFormat: PresentationWebcast: http://ir.cymabay.com/event
ZacksHere's Why Momentum in CymaBay Therapeutics Inc. (CBAY) Should Keep going
CymaBay Therapeutics Inc. (CBAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
ZacksWall Street Analysts Predict a 40.32% Upside in CymaBay Therapeutics Inc. (CBAY): Here's What You Should Know
The consensus price target hints at a 40.3% upside potential for CymaBay Therapeutics Inc. (CBAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Insider MonkeyCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q4 2022 Earnings Call Transcript
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q4 2022 Earnings Call Transcript March 16, 2023 Operator: Good day ladies and gentlemen and welcome to CymaBay’s Fourth Quarter and Full-Year 2022 Financial Results and Business Update Conference Call. Following the formal remarks, we will open the call for your questions. Please be advised that the call will be recorded […]
- Simply Wall St.
When Will CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Breakeven?
With the business potentially at an important milestone, we thought we'd take a closer look at CymaBay Therapeutics...
- GlobeNewswire
CymaBay Reports Fourth Quarter and Year Ended December 31, 2022 Financial Results and Provides Corporate Update
Conference call and webcast today at 4:30 p.m. ETNEWARK, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the year and fourth quarter ended December 31, 2022. Sujal Shah, President and CEO of CymaBay, stated, “We are off to a fast start in 2023 after making significant
- GlobeNewswire
CymaBay Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
NEWARK, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, March 16, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2022 and to provide a business update. Conference Call DetailsT
- GlobeNewswire
CymaBay Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
NEWARK, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the Oppenheimer 33rd Annual Healthcare Conference. Oppenheimer 33rd Annual Healthcare ConferenceDate: Monday, March 13Time: 11:20 am Eastern TimeFormat: Fireside ChatWebcast: http://ir.cymabay.com/events About CymaBayCym
- GlobeNewswire
CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference
NEWARK, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Securities Global Biopharma Conference. SVB Securities Global Biopharma ConferenceDate: Wednesday, February 15Time: 3:40 pm Eastern TimeLocation: VirtualFormat: Fireside ChatWebcast: http://ir.cymabay.com/events A
GlobeNewswireCymaBay Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
NEWARK, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need announced the closing, on January 26, 2023, of its previously announced underwritten public offering of its common stock and pre-funded warrants. CymaBay sold 11,821,428 shares of its common stock in the offering, including 1,821,428 shares pursuant to the full exer
- GlobeNewswire
CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
NEWARK, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced the pricing of its previously announced underwritten public offering of common stock and pre-funded warrants. CymaBay is selling 10,000,000 shares of common stock and pre-funded warrants to purchase 2,142,857 shares of common stock in the offering.
- GlobeNewswire
CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
NEWARK, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by CymaBay. CymaBay intends to grant the underwriters a
ZacksHere's What Could Help CymaBay Therapeutics Inc. (CBAY) Maintain Its Recent Price Strength
If you are looking for stocks that are well positioned to maintain their recent uptrend, CymaBay Therapeutics Inc. (CBAY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
- GlobeNewswire
CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis
Advances strategy to partner seladelpar for PBC outside U.S. Brings in approximately $34.0 million upfront payment Japan represents an important market with no currently approved second line treatment NEWARK, Calif. and TOKYO, Jan. 08, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) (“CymaBay” or the “Company”) announced today that it has entered into a collaboration and license agreement with Kaken Pharmaceutical Co., Ltd. (“Kaken”) for the development and commercialization i
- Simply Wall St.
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) may have lost US$34m in value but insiders who invested last year have seen gains of around US$72k to date
Insiders who bought CymaBay Therapeutics, Inc. ( NASDAQ:CBAY ) stock lover the last 12 months are probably not as...
ZacksIs Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?
Here is how Gilead Sciences (GILD) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.